{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:12:49Z","timestamp":1790284369823,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the European Union","award":["PNRR-MAD-2022-12375740 M6C2"],"award-info":[{"award-number":["PNRR-MAD-2022-12375740 M6C2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>In the past decade, our understanding of psoriasis pathogenesis has made significant steps forward, leading to the development of multiple game-changing therapies. While psoriasis primarily affects the skin, it is increasingly recognized as a systemic disease that can have effects beyond the skin. Obesity is associated with more severe forms of psoriasis and can potentially worsen the systemic inflammation and metabolic dysfunction seen in psoriatic patients. The exact mechanisms underlying the link between these two conditions are not fully understood, but it is believed that chronic inflammation and immune dysregulation play a role. In this review, we examine the existing body of knowledge regarding the intersection of pathogenic processes responsible for psoriasis and obesity. The ability of biological therapies to reduce systemic and obesity-related inflammation in patients with psoriasis will be also discussed.<\/jats:p>","DOI":"10.3390\/life14060733","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:38:56Z","timestamp":1717735136000},"page":"733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-3262","authenticated-orcid":false,"given":"Emanuele","family":"Scala","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Immunology, Istituto Dermopatico dell\u2032Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Istituto Dermopatico dell\u2032Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-6833","authenticated-orcid":false,"given":"Cristina","family":"Albanesi","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Istituto Dermopatico dell\u2032Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6783","authenticated-orcid":false,"given":"Stefania","family":"Madonna","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology, Istituto Dermopatico dell\u2032Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: Epidemiology","volume":"25","author":"Gudjonsson","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: Global epidemiology and pathogenesis","volume":"15","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1002\/ski2.33","article-title":"Psychosocial aspects of obesity in adults with psoriasis: A systematic review","volume":"1","author":"Pavlova","year":"2021","journal-title":"Ski. Health Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"1","author":"Carrascosa","year":"2014","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vata, D., Tarcau, B.M., Popescu, I.A., Halip, I.A., Patrascu, A.I., Gheuca Solovastru, D.F., Mocanu, M., Chiriac, P.C., and Gheuca Solovastru, L. (2023). Update on Obesity in Psoriasis Patients. Life, 13.","DOI":"10.3390\/life13101947"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/sj.jid.5701140","article-title":"Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort","volume":"128","author":"Smith","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3389\/fimmu.2018.02239","article-title":"Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease","volume":"9","author":"Israel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13671-013-0066-6","article-title":"Genetic Epidemiology of Psoriasis","volume":"3","author":"Gupta","year":"2014","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Balato, A., Zink, A., Babino, G., Buononato, D., Kiani, C., Eyerich, K., Ziehfreund, S., and Scala, E. (2022). The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers. Life, 12.","DOI":"10.3390\/life12122026"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13555-020-00363-1","article-title":"Stigmatization and Quality of Life in Patients with Psoriasis","volume":"10","author":"Jankowiak","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"a015354","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Villanova","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.20080129","article-title":"Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment","volume":"206","author":"Albanesi","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients","volume":"113","author":"Austin","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"ref_23","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","article-title":"The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., and Romanelli, M. (2018). Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010179"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/138920010791196328","article-title":"Pathobiology of chronic inflammatory skin diseases: Interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs","volume":"11","author":"Albanesi","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K.M., Gulati, N., Mitsui, H., Guttman-Yassky, E., and Su\u00e1rez-Fari\u00f1as, M. (2014). IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090284"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Capon, F. (2017). The Genetic Basis of Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122526"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of Psoriasis: A comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_30","first-page":"1363","article-title":"Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders","volume":"17","author":"Balato","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e15622","DOI":"10.1111\/dth.15622","article-title":"Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: A cross-sectional study in Italy","volume":"35","author":"Scala","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.apsb.2023.01.012","article-title":"Pathophysiology of obesity and its associated diseases","volume":"13","author":"Jin","year":"2023","journal-title":"Acta Pharm. Sinica. B"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1038\/oby.2002.203","article-title":"Classification of obesity and assessment of obesity-related health risks","volume":"10","author":"Aronne","year":"2002","journal-title":"Obes. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fphar.2020.00117","article-title":"Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Costache, D.O., Blejan, H., Cojocaru, D.L., Ioni\u021b\u0103, G.A., Poenaru, M., Constantin, M.M., Costache, A.C., C\u0103runtu, C., Balaban, D.V., and Costache, R.S. (2024). Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet\u2014A Comprehensive Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052660"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.annder.2015.06.024","article-title":"Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases","volume":"143","author":"Phan","year":"2016","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr. Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.jid.2017.07.822","article-title":"Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study","volume":"137","author":"Snekvik","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/jdv.12001","article-title":"Obesity, waist circumference, weight change and the risk of psoriasis in US women","volume":"27","author":"Kumar","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jid.2018.11.023","article-title":"A Transethnic Mendelian Randomization Study Identifies Causality of Obesity on Risk of Psoriasis","volume":"139","author":"Ogawa","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Czarnecka, A., Purzycka-Bohdan, D., Zab\u0142otna, M., Bohdan, M., Nowicki, R.J., and Szczerkowska-Dobosz, A. (2023). Considerations of the Genetic Background of Obesity among Patients with Psoriasis. Genes, 14.","DOI":"10.3390\/genes14030594"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dopytalska, K., Ciechanowicz, P., Wiszniewski, K., Szyma\u0144ska, E., and Walecka, I. (2021). The Role of Epigenetic Factors in Psoriasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179294"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mahmoud, A.M. (2022). An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031341"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","article-title":"Obesity and risk of incident psoriatic arthritis in US women","volume":"71","author":"Li","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/1744666X.2016.1201423","article-title":"Crosstalk between skin inflammation and adipose tissue-derived products: Pathogenic evidence linking psoriasis to increased adiposity","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","article-title":"The pharmacological management of patients with comorbid psoriasis and obesity","volume":"20","author":"Chiricozzi","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/exd.12691","article-title":"Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice","volume":"24","author":"Kanemaru","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5551\/jat.3939","article-title":"Adipose tissue, inflammation and atherosclerosis","volume":"17","author":"Gustafson","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs, D., Fazekas, F., Ol\u00e1h, A., and T\u00f6r\u0151csik, D. (2020). Adipokines in the Skin and in Dermatological Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239048"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/ijpvm.IJPVM_193_20","article-title":"Adiponectin: Role in Physiology and Pathophysiology","volume":"11","author":"Nguyen","year":"2020","journal-title":"Int. J. Prev. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2008.07.045","article-title":"Effects of adiponectin on growth and differentiation of human keratinocytes\u2013implication of impaired wound healing in diabetes","volume":"374","author":"Kawai","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdermsci.2010.06.004","article-title":"Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes","volume":"59","author":"Takahashi","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.1102588","article-title":"Adiponectin induces dendritic cell activation via PLC\u03b3\/JNK\/NF-\u03baB pathways, leading to Th1 and Th17 polarization","volume":"188","author":"Jung","year":"2012","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1074\/jbc.M109.088708","article-title":"Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype","volume":"285","author":"Ohashi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3389\/fimmu.2019.02555","article-title":"Adiponectin Limits IFN-\u03b3 and IL-17 Producing CD4 T Cells in Obesity by Restraining Cell Intrinsic Glycolysis","volume":"10","author":"Surendar","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1365-2133.2008.08759.x","article-title":"Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis","volume":"159","author":"Kaur","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdermsci.2009.02.009","article-title":"Serum high molecular weight adiponectin levels are decreased in psoriasis patients","volume":"55","author":"Shibata","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4049\/jimmunol.1002352","article-title":"Regulation of chemerin chemoattractant and antibacterial activity by human cysteine cathepsins","volume":"187","author":"Kulig","year":"2011","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/obr.12009","article-title":"Towards an integrative approach to understanding the role of chemerin in human health and disease","volume":"14","author":"Rourke","year":"2013","journal-title":"Obes. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Banas, M., Zegar, A., Kwitniewski, M., Zabieglo, K., Marczynska, J., Kapinska-Mrowiecka, M., LaJevic, M., Zabel, B.A., and Cichy, J. (2015). The expression and regulation of chemerin in the epidermis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117830"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1002\/jcb.27936","article-title":"Chemerin\/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-\u03baB signaling","volume":"120","author":"Wang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_64","first-page":"531","article-title":"Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities","volume":"36","author":"Gerkowicz","year":"2020","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.12118","article-title":"Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/beem.2002.0223","article-title":"Peripheral metabolic actions of leptin","volume":"16","author":"Muoio","year":"2002","journal-title":"Best Pract. Research. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.7624776","article-title":"Effects of the obese gene product on body weight regulation in ob\/ob mice","volume":"269","author":"Pelleymounter","year":"1995","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.25122\/jml-2021-0153","article-title":"Leptin hormone and its effectiveness in reproduction, metabolism, immunity, diabetes, hopes and ambitions","volume":"14","author":"Alburghaif","year":"2021","journal-title":"J. Med. Life"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/exd.12162","article-title":"Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro\u2014A possible reason for increased severity of psoriasis in patients with a high body mass index","volume":"22","author":"Xue","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI9148","article-title":"Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair","volume":"106","author":"Frank","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1096\/fj.03-0068fje","article-title":"Leptin is an autocrine\/paracrine regulator of wound healing","volume":"17","author":"Murad","year":"2003","journal-title":"FASEB J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2007.01.011","article-title":"A key role of leptin in the control of regulatory T cell proliferation","volume":"26","author":"Procaccini","year":"2007","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-6143.2012.04283.x","article-title":"Leptin deficiency modulates allograft survival by favoring a Th2 and a regulatory immune profile","volume":"13","author":"Bassi","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2133.2008.08655.x","article-title":"Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation","volume":"159","author":"Johnston","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1096\/fsb2fasebj.12.1.57","article-title":"Leptin regulates proinflammatory immune responses","volume":"12","author":"Loffreda","year":"1998","journal-title":"FASEB J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.167.8.4593","article-title":"High-dose leptin activates human leukocytes via receptor expression on monocytes","volume":"167","author":"Pockley","year":"2001","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.4049\/jimmunol.174.11.6820","article-title":"Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming","volume":"174","author":"Mattioli","year":"2005","journal-title":"J. Immunol."},{"key":"ref_78","first-page":"273","article-title":"Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: A systematic review and meta-analysis","volume":"179","author":"Kyriakou","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2337\/diabetes.53.7.1671","article-title":"Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting","volume":"53","author":"Rajala","year":"2004","journal-title":"Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"S\u0142uczanowska-G\u0142abowska, S., Staniszewska, M., Marchlewicz, M., Duchnik, E., \u0141uczkowska, K., Safranow, K., Machali\u0144ski, B., and Pawlik, A. (2023). Adiponectin, Leptin and Resistin in Patients with Psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020663"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/bph.13505","article-title":"Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine","volume":"173","author":"Grolla","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cphy.c160029","article-title":"Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase\/Visfatin","volume":"7","author":"Carbone","year":"2017","journal-title":"Compr. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e15503","DOI":"10.5812\/ijem.15503","article-title":"Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome","volume":"12","author":"Farshchian","year":"2014","journal-title":"Int. J. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/ecn.2015.0370","article-title":"Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome","volume":"26","author":"Gul","year":"2015","journal-title":"Eur. Cytokine Netw."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Mercurio, L., Morelli, M., Scarponi, C., Scaglione, G.L., Pallotta, S., Avitabile, D., Albanesi, C., and Madonna, S. (2021). Enhanced NAMPT-Mediated NAD Salvage Pathway Contributes to Psoriasis Pathogenesis by Amplifying Epithelial Auto-Inflammatory Circuits. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136860"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phrs.2018.06.022","article-title":"NAMPT: A pleiotropic modulator of monocytes and macrophages","volume":"135","author":"Travelli","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104147","DOI":"10.1016\/j.isci.2022.104147","article-title":"Extracellular nicotinamide phosphoribosyltransferase boosts IFN\u03b3-induced macrophage polarization independently of TLR4","volume":"25","author":"Colombo","year":"2022","journal-title":"iScience"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/en.2010-1481","article-title":"Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes","volume":"152","author":"Kanda","year":"2011","journal-title":"Endocrinology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ajpath.2013.01.044","article-title":"Visfatin enhances the production of cathelicidin antimicrobial peptide, human \u03b2-defensin-2, human \u03b2-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin","volume":"182","author":"Hau","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2133.2012.10980.x","article-title":"Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity","volume":"167","author":"Ismail","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jcla.21850","article-title":"Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity","volume":"30","author":"Okan","year":"2016","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Torretta, S., Colombo, G., Travelli, C., Boumya, S., Lim, D., Genazzani, A.A., and Grolla, A.A. (2020). The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5). Cells, 9.","DOI":"10.3390\/cells9020496"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1038\/srep13135","article-title":"Unique Toll-Like Receptor 4 Activation by NAMPT\/PBEF Induces NF\u03baB Signaling and Inflammatory Lung Injury","volume":"5","author":"Camp","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, tildrakizumab, and risankizumab in a real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.autrev.2016.01.010","article-title":"Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy","volume":"15","author":"Iannone","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/09546634.2021.1901845","article-title":"Effects of TNF inhibitors and an IL12\/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: A 48-week comparative study","volume":"33","author":"Onsun","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","article-title":"Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment","volume":"24","author":"Renzo","year":"2011","journal-title":"Dermatol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","article-title":"Anti-tumour necrosis factor-\u03b1 therapy increases body weight in patients with chronic plaque psoriasis: A retrospective cohort study","volume":"22","author":"Gisondi","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/039463200902200124","article-title":"Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis","volume":"22","author":"Esposito","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cyto.2014.06.005","article-title":"TNF-\u03b1 reduces g0s2 expression and stimulates lipolysis through PPAR-\u03b3 inhibition in 3T3-L1 adipocytes","volume":"69","author":"Jin","year":"2014","journal-title":"Cytokine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1194\/jlr.M400295-JLR200","article-title":"Characterization of differentiated subcutaneous and visceral adipose tissue from children: The influences of TNF-alpha and IGF-I","volume":"46","author":"Grohmann","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jdv.13131","article-title":"Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy","volume":"29","author":"Pina","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1172\/JCI119824","article-title":"Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes","volume":"100","author":"Kirchgessner","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/14656566.2019.1603294","article-title":"Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity?","volume":"20","author":"Dalamaga","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jdv.14252","article-title":"The effect of bodyweight on the efficacy and safety of ixekizumab: Results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis","volume":"31","author":"Reich","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"253046","DOI":"10.1155\/2013\/253046","article-title":"Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism","volume":"2013","author":"Shi","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2040622320944777","DOI":"10.1177\/2040622320944777","article-title":"Changes in metabolic parameters in psoriatic patients treated with secukinumab","volume":"11","author":"Wang","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e15793","DOI":"10.1111\/dth.15793","article-title":"Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study","volume":"35","author":"Ricceri","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"178","author":"Gordon","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"E1720","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus","volume":"97","author":"Wouters","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/dom.12839","article-title":"The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism","volume":"19","author":"Kahles","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/en.2009-0108","article-title":"Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B","volume":"150","author":"Zhang","year":"2009","journal-title":"Endocrinology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"E1476","DOI":"10.1210\/jc.2014-1430","article-title":"Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome","volume":"99","author":"Jensterle","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12944-015-0039-9","article-title":"Increased serum resistin levels correlate with psoriasis: A meta-analysis","volume":"14","author":"Huang","year":"2015","journal-title":"Lipids Health Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/1346-8138.12121","article-title":"Adiponectin levels in patients with psoriasis: A meta-analysis","volume":"40","author":"Zhu","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/ced.12171","article-title":"Leptin levels in patients with psoriasis: A meta-analysis","volume":"38","author":"Zhu","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: Not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2005.02.023","article-title":"Adipose tissue, adipokines, and inflammation","volume":"115","author":"Fantuzzi","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/09546634.2014.915917","article-title":"Serum adiponectin and leptin levels in psoriatic patients according to topical treatment","volume":"26","author":"Baran","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ijd.12706","article-title":"Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-\u03b1 inhibitors: Results of a retrospective analysis","volume":"54","author":"Campanati","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1468-3083.2010.03647.x","article-title":"Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy","volume":"24","author":"Coimbra","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000351769","article-title":"The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: A noncontrolled study","volume":"227","author":"Karadag","year":"2013","journal-title":"Dermatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12026-013-8410-2","article-title":"Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab","volume":"56","author":"Lora","year":"2013","journal-title":"Immunol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/09546634.2013.848260","article-title":"Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment","volume":"25","author":"Puig","year":"2014","journal-title":"J. Dermatol. Treat."},{"key":"ref_136","first-page":"667","article-title":"Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: Induction of elevated serum adiponectin levels following therapy","volume":"164","author":"Shibata","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Stanescu, A.M.A., Simionescu, A.A., Florea, M., and Diaconu, C.C. (2021). Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040251"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","article-title":"Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas","volume":"115","author":"Vilarrasa","year":"2024","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., and Fabbrocini, G. (2021). Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 10.","DOI":"10.3390\/cells10082094"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/6\/733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:55:03Z","timestamp":1760108103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/6\/733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":140,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["life14060733"],"URL":"https:\/\/doi.org\/10.3390\/life14060733","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}